3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Genitourinary
3
CNS
3
Breast
3
Thoracic
2
Gastrointestinal
2
Dermatologic
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Influenza, Human
1
Interventions
Dexamethasone
293
Lenalidomide
162
Bortezomib
160
Cyclophosphamide
121
Calcium Dobesilate
118
Melphalan
116
fludarabine phosphate
75
carfilzomib
62
pomalidomide
57
Whole-Body Irradiation
57
Mycophenolic Acid
56
Granulocyte Colony-Stimulating Factor
55
Peripheral Blood Stem Cell Transplantation
54
Filgrastim
54
fludarabine
50
daratumumab
50
Tacrolimus
45
Busulfan
45
ixazomib
42
Thalidomide
37
Cyclosporine
32
Stem Cell Transplantation
29
dexamethasone acetate
28
Antilymphocyte Serum
26
dexamethasone 21-phosphate
23
plerixafor
21
elotuzumab
20
auricularum
20
belantamab mafodotin
19
Prednisone
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Vaccines
×
Plasma cell
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts